Quest Diagnostics (DGX) Earnings: 1Q Adjusted EPS Surpasses Estimates at $2.21

Quest Diagnostics on Smartkarma

Analysts on Smartkarma, such as Baptista Research, are bullish on Quest Diagnostics due to the company’s strategic moves and strong financial performance. In one report titled “Quest Diagnostics: Enhanced Offerings In Cardiometabolic Testing & Autoimmune Disorders Catalyzing Growth!,” Baptista Research highlighted the company’s revenue growth driven by acquisitions and organic growth. Quest Diagnostics reported a 14.5% increase in revenue for the fourth quarter of 2024, with organic revenue growth accounting for nearly 5%. The completion of key acquisitions, like LifeLabs in Canada, has strengthened the company’s market position in the physician and hospital channels.

Furthermore, in another report titled “Quest Diagnostics: Expansion into New Markets through Strategic Acquisitions As A Critical Growth Catalyst! – Major Drivers,” Baptista Research emphasized Quest Diagnostics‘ robust performance in the third quarter driven by total revenue growth of 8.5%. Strategic initiatives such as new customer acquisitions, expanding business with existing customers, and acquisitions like LifeLabs have fueled growth and expanded the company’s market presence in both Canada and the U.S. This positive sentiment from analysts underscores the growth potential and strategic direction of Quest Diagnostics.

A look at Quest Diagnostics Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Quest Diagnostics Incorporated, a company providing diagnostic testing services, has received mixed scores across various key factors according to Smartkarma Smart Scores. While scoring a solid 3 in Value, Dividend, Growth, and Resilience, it stands out with a strong score of 5 in Momentum. This high momentum score suggests that the company is experiencing positive market sentiment and potentially strong upward price movement in the future. Despite average scores in other areas, Quest Diagnostics‘ high momentum score indicates potential for growth and market outperformance in the long term.

Quest Diagnostics operates a national network of laboratories and service centers, offering various diagnostic testing services. With a diversified portfolio including routine medical testing, esoteric testing, drugs of abuse testing, and anatomic pathology testing, the company plays a crucial role in the healthcare industry. The balanced scores across different key factors indicate a stable foundation, while the high momentum score suggests a promising outlook for Quest Diagnostics in the long term.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma